A venture-backed biotech company developing a clinical stage asset for the treatment of early-stage cancer was populating a data room and preparing for negotiations with a major pharma company. We were asked to prepare an expert review paper for the lead product, which summarized the evidence base for proposed efficacy in the primary target market and the potential mechanism(s) of action responsible for market performance. The compound, which had significant clinical exposure, was active through at least three mainstream anti-cancer pathways, each of which could potentially account for some or all of the observed market activity.
Our team, which included a former pharma research director, was able to collate all relevant literature into one framework.
The report was included in the data room where it provided support for the prospective partner’s research team.Back